

10/553120

Docket No. 279431US0PCT

JC20 Rec'd PCT/PTO 14 OCT 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Tatsuo KIMURA, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/JP04/05355

GAU:

FILED: Herewith

EXAMINER:

FOR: PREVENTIVE/REMEDY FOR RETINAL NERVE DISEASES CONTAINING ALKYL ETHER DERIVATIVES  
OR SALTS THEREOF

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

## REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

## RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).


## CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

## DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Corwin P. Umbach, Ph.D.

Registration No. 40,211

Surinder Sachar

Registration No. 34,423

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./

100/55120

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 279431US0PCT		SERIAL NO. 55120 New U.S. PCT Application Based on PCT/JP04/05355	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Tatsuo KIMURA, et al.			
				FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	03/035647	05/01/03	WO(English abstract only)		NO	
Abstract only	AP	02/100833	12/19/02	WO(English abstract only)		NO	
Abstract only	AQ	02/30420	04/18/02	WO(with English abstract)		NO	
	AR	8-506807	07/23/96	JP(Equivalent of WO 94/13275)		NO	
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
not considered	AW	Hyojun Ganka Gaku, 7 <sup>th</sup> edition, pages 103-107, Igaku-Shoin Ltd., 1998.					
Abstract only	AX	Haruki, ABE: "Atarashii Ganka, Vol. 19, No. 7, pages 903-912, 2002 ( with English abstract).					
	AY	"Agouron buys drug discovery company" "Chiroscience steps up licensing talks", SCRIP No. 2229, page 13, May 6/9 <sup>th</sup> 1997.					
	AZ	"Allergan's 1997 sales fall", SCRIP No. 2307, page 10, February 6 <sup>th</sup> 1998.				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner /Gigi Huang/					Date Considered 10/21/2008		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./

10/553120

JC20 Rec'd PCT/PTO 14 OCT 2005

New U.S. PCT Application Based on PCT/JP04/05355  
Docket No.: 279431US0PCT

STATEMENT OF RELEVANCY

- 1) References AO-AQ have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) Reference \_\_\_\_\_ have been cited in the corresponding \_\_\_\_\_ Search Report. A copy of this reference is being submitted herewith.
- 3) References AR and AW-AZ are discussed in the specification. A copy of these references is being submitted here with.
- 4) Reference \_\_\_\_\_ is additional prior art known to Applicant. A copy of these references is being submitted herewith.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.H./